药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

休市中 12-19 16:08:04

163.900

-4.100

-2.44%

最高173.000	最低163.300	成交量51.45万
今开169.600	昨收168.000	日振幅5.77%
总市值650.68亿	流通市值494.43亿	总股本3.97亿
成交额8,631万	换手率0.17%	流通股本3.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":163.9,"timestamp":1766131684724,"preClose":168,"halted":0,"volume":514500,"delay":0,"floatShares":301666673,"shares":397000000,"eps":-0.7963437980219285,"marketStatus":"休市中","change":-4.1,"latestTime":"12-19 16:08:04","open":169.6,"high":173,"low":163.3,"amount":86309150,"amplitude":0.057738,"askPrice":163.9,"askSize":3000,"bidPrice":163.8,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.6870008486954221,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":168,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":0.5418241942002083,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"2592138749","title":"药捷安康-B(02617):替恩戈替尼片新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592138749","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592138749?lang=zh_cn&edition=full","pubTime":"2025-12-19 08:21","pubTimestamp":1766103707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，替恩戈替尼片的新药上市申请已获中国国家药品监督管理局药品审评中心受理，拟用于治疗既往至少接受过一种系统性治疗和FGFR抑制剂治疗的晚期、转移性或不可手术切除的胆管癌成人患者。此前，替恩戈替尼片此适应症已获批准纳入优先审评品种名单及突破性治疗品种名单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B(02617):替恩戈替尼片新药上市申请获国家药品监督管理局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2592634992","title":"药捷安康-B(02617)发表核心产品替恩戈替尼针对胆管癌的探索性临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2592634992","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592634992?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:02","pubTimestamp":1765972929,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 公布，近日，公司核心产品替恩戈替尼在美国开展的针对胆管癌的探索性临床2期结果在《柳叶刀，胃肠病和肝病学》上发表。替恩戈替尼可克服FGFR2融合阳性胆管癌患者对FGFR抑制剂的获得性耐药，并在其他FGFR基因改变的胆管癌患者中显示出抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1150760712","title":"港股异动｜生物医药股上扬，药捷安康涨超17%，昭衍新药涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150760712","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150760712?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:50","pubTimestamp":1765939813,"startTime":"0","endTime":"0","summary":"轩竹生物涨超5%，银诺医药涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22a0e03e703ab82b83863db78ab69d04","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","02575","06127","02591"],"gpt_icon":0},{"id":"2592957760","title":"药捷安康-B(02617.HK)拉升近14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592957760","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592957760?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:44","pubTimestamp":1765939453,"startTime":"0","endTime":"0","summary":"每经AI快讯，药捷安康-B(02617.HK)拉升近14%，截至发稿涨13.85%，报166.1港元，成交额1.12亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512173594031742.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"22a0e03e703ab82b83863db78ab69d04","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512173594031742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2592957584","title":"港股异动 | 药捷安康-B(02617)拉升近14% 近日宣布在《柳叶刀》子刊发表替恩戈替尼积极临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2592957584","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592957584?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:33","pubTimestamp":1765938839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B拉升近14%，截至发稿，涨13.85%，报166.1港元，成交额1.12亿港元。消息面上，据药捷安康官微消息，近日，公司宣布，核心产品替恩戈替尼在美国开展的针对胆管癌的探索性临床2期结果在《柳叶刀，胃肠病和肝病学》上发表。据悉，替恩戈替尼是一款自主研发、注册性临床阶段的创新多靶点小分子激酶抑制剂，通过靶向肿瘤细胞和改善肿瘤微环境发挥抗肿瘤作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22a0e03e703ab82b83863db78ab69d04","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2590313951","title":"港股药捷安康-B尾盘跳水跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590313951","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590313951?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:31","pubTimestamp":1765265502,"startTime":"0","endTime":"0","summary":"港股药捷安康-B尾盘跳水跌超10%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512093586422675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2588466011","title":"药捷安康-B(02617)：替恩戈替尼片获国家药品监督管理局批准纳入优先审评品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2588466011","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588466011?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:12","pubTimestamp":1764753145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，替恩戈替尼片已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)批准纳入优先审评品种名单，拟定适应症为：用于既往至少接受过一种系统性治疗和FGFR抑制剂治疗的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。此前，替恩戈替尼已获NMPA授予治疗胆管癌的突破性治疗品种认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B(02617)：替恩戈替尼片获国家药品监督管理局批准纳入优先审评品种名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2588083249","title":"药捷安康-B盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588083249","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588083249?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:17","pubTimestamp":1764645460,"startTime":"0","endTime":"0","summary":"2025年12月02日早盘11时17分，药捷安康-B股票出现异动，股价大幅跳水5.10%。截至发稿，该股报186.000港元/股，成交量16.28万股，换手率0.05%，振幅6.58%。资金方面，该股资金流入721.28万港元，流出1528.15万港元。药捷安康-B股票所在的生物技术行业中，整体跌幅为1.60%。药捷安康-B公司简介：药捷安康(南京)科技股份有限公司是一家从事生物制药的中国公司,主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512021117409525dd7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512021117409525dd7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2586656782","title":"药捷安康-B11月26日主力净流入174.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586656782","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586656782?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:15","pubTimestamp":1764144943,"startTime":"0","endTime":"0","summary":"11月26日, 药捷安康-B股价涨2.32%，报收202.60元，成交金额1.1亿元，换手率0.18%，振幅5.20%，量比0.65。药捷安康-B今日主力资金净流入174.2万元，上一交易日主力净流出178.2万元。该股近5个交易日下跌0.10%，主力资金累计净流出13.5万元；近20日主力资金累计净流入6598.1万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126161949a7127c3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126161949a7127c3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2584257229","title":"药捷安康-B11月19日获主力加仓217.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584257229","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584257229?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:15","pubTimestamp":1763540155,"startTime":"0","endTime":"0","summary":"11月19日, 药捷安康-B股价涨1.10%，报收202.80元，成交金额1.1亿元，换手率0.19%，振幅4.34%，量比0.47。药捷安康-B今日主力资金净流入217.6万元，上一交易日主力净流入25万元。该股近5个交易日下跌3.90%，主力资金累计净流出17.0万元；近20日主力资金累计净流入7730.5万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119162134950dff1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119162134950dff1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2584938727","title":"药石科技：公司持有的药捷安康股份市值变化，公司发行的可转债完成转股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584938727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584938727?lang=zh_cn&edition=full","pubTime":"2025-11-18 17:48","pubTimestamp":1763459289,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技(300725)11月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问下公司今年三季报每股净资产突然大增的原因？药石科技回复：投资者您好，公司三季度末净资产较年初发生变化的主要原因系：公司持有的药捷安康股份市值变化，公司发行的可转债完成转股。详细信息请查阅公司《2025年第三季度报告》中“主要会计数据和财务指标发生变动的情况及原因”部分，谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800026717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02617","BK0229","300725"],"gpt_icon":0},{"id":"2583523515","title":"药捷安康-B11月13日主力净流出409.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523515","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583523515?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:15","pubTimestamp":1763021705,"startTime":"0","endTime":"0","summary":"11月13日, 药捷安康-B股价跌1.52%，报收207.00元，成交金额2.6亿元，换手率0.41%，振幅6.57%，量比0.51。药捷安康-B今日主力资金净流出409.9万元，上一交易日主力净流入29.8万元。该股近5个交易日下跌5.81%，主力资金累计净流入1684.0万元；近20日主力资金累计净流入7651.5万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113161516a6f67580&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113161516a6f67580&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2582942317","title":"药捷安康-B盘中异动 大幅拉升4.77%报224.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582942317","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582942317?lang=zh_cn&edition=full","pubTime":"2025-11-12 09:40","pubTimestamp":1762911658,"startTime":"0","endTime":"0","summary":"2025年11月12日早盘09时40分，药捷安康-B股票出现异动，股价急速拉升4.77%。截至发稿，该股报224.000港元/股，成交量23.8628万股，换手率0.08%，振幅5.14%。资金方面，该股资金流入1984.02万港元，流出1475.2万港元。药捷安康-B股票所在的生物技术行业中，整体涨幅为1.22%。其相关个股中，中生北控生物科技、药捷安康-B、百济神州涨幅较大，振幅较大的相关个股有荣昌生物、来凯医药-B、药捷安康-B，振幅分别为8.11%、7.77%、5.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111209405897639ba5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111209405897639ba5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2582317920","title":"药捷安康-B11月11日主力净流出704.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2582317920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582317920?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:15","pubTimestamp":1762848955,"startTime":"0","endTime":"0","summary":"11月11日, 药捷安康-B股价跌8.24%，报收213.80元，成交金额3.3亿元，换手率0.50%，振幅10.21%，量比0.51。药捷安康-B今日主力资金净流出704.0万元，上一交易日主力净流入1984.6万元。该股近5个交易日上涨18.12%，主力资金累计净流入5642.6万元；近20日主力资金累计净流入8031.5万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111162149976214a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111162149976214a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2582844837","title":"香港IPO集资额重登全球之巅 惠理创始人谢清海剖析背后的“赢家密码”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582844837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582844837?lang=zh_cn&edition=full","pubTime":"2025-11-10 14:01","pubTimestamp":1762754460,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，多只重磅新股在港交所上市，推动香港新股市场今年表现亮丽，重夺首次公开发行集资额冠军豪无悬念。谢清海称，将香港建设、巩固和发展成为国际金融中心，不仅对香港本身至关重要，对国家同样重要。香港行政长官李家超上周出席国际金融领袖投资峰会主峰会时表示，香港今年首10个月，新股集资额全球排名第一，期内共有80宗IPO，集资额超过260亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1116","IPO","BK1156","BK1198","LU1960683339.HKD","LU1993786604.SGD","HEXmain","LU1807302812.USD","BK1610","00806","02617","BK1161"],"gpt_icon":1},{"id":"2582252819","title":"智通港股通资金流向统计(T+2)|11月10日","url":"https://stock-news.laohu8.com/highlight/detail?id=2582252819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582252819?lang=zh_cn&edition=full","pubTime":"2025-11-10 07:31","pubTimestamp":1762731060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月5日,南方恒生科技、阿里巴巴-W、小米集团-W南向资金净流入金额位列市场前三，分别净流入12.86 亿、8.85 亿、6.50 亿华虹半导体、中芯国际、哔哩哔哩-W南向资金净流出金额位列市场前三，分别净流出-6.42 亿、-5.05 亿、-1.88 亿在净流入比方面，青岛银行、中国通号、大唐新能源以83.58%、56.27%、55.14%位列市场前三。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03969","00990","02419","02382","02800","00548","03403","06869","HXXD.SI","02828","02601","81810","00966","02899","02039","KSTmain","00308","01810","01055","IE00B3M56506.USD","01398","HBBD.SI","00257","09626","80883","09988","01798","02273","81024","00168","XIACY","00991","00639","09636","00667","00763","89988","03143","02460","03033","MCHmain","02192","02617","00939","03866","00883"],"gpt_icon":1},{"id":"2581080038","title":"生物医药股普跌 药捷安康-B(02617)跌5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581080038","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581080038?lang=zh_cn&edition=full","pubTime":"2025-11-06 10:07","pubTimestamp":1762394826,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药股普跌，药捷安康-B 跌5.34%，科伦博泰生物-B跌5.20%，康诺亚-B跌4.52%，药师帮跌4.46%，映恩生物-B跌3.95%，佰泽医疗跌3.69%，乐普生物-B跌3.32%，再鼎医药跌3.16%，脑动极光-B跌2.96%，亚盛医药-B跌2.75%。交银国际表示，医药行业板块3Q25业绩呈现边际复苏态势，其中与创新产业链关联紧密的化药/生物药公司和CXO板块表现较优，集采影响逐步出清的子板块也有改善迹象。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1587","06990","BK1588","HK0000500386.USD","02617","09606","BK1197","02157","399441","LU2543165471.USD","09688","02609","BK1574","LU0196878994.USD","161726","06681","06855","BK1583","09885","BK1189","LU2488822045.USD","BK1161","BK1209","HK0000252152.HKD","02162"],"gpt_icon":0},{"id":"1138049857","title":"港股综述｜三大指数午后回暖！航空股全天强势，锂电池、电力设备股强势拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1138049857","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138049857?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:33","pubTimestamp":1762331602,"startTime":"0","endTime":"0","summary":"恒指微跌0.07%，航空股全天维持强势，锂电池、电力设备股强势拉升11月5日，午后市场明显回暖，恒生指数、国企指数一度转涨，最终分别收跌0.07%及0.11%，恒指在26000点附近反复震荡，恒生科技指数跌0.56%相对最弱，三大指数均呈现低开高走行情。A股行情A股收评：低开高走！全市场成交额1.89万亿元，较前一交易日缩量441亿元，近3400股上涨。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0e8db0f06f95058464db3c9adf61f49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","HSI","HSTECH"],"gpt_icon":0},{"id":"2581495087","title":"药捷安康(2617.HK)尾盘拉升涨超21%，与Neurocrine达成项目合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2581495087","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581495087?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:17","pubTimestamp":1762330622,"startTime":"0","endTime":"0","summary":"药捷安康-B尾盘拉升涨超21%。药捷安康近日公告，Neurocrine与本公司订立一项付特许权使用费的专利转让及研究合作协议，以开发NLRP3抑制剂，用于治疗多种疾病。根据该协议，公司将有权获得预付款，并且根据Neurocrine的开发和商业化进展，公司可能会收到与研发里程碑和销售里程碑相关的进一步里程碑付款，该协议的总潜在价值为8.815亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251105/31769637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2581246817","title":"药捷安康-B11月05日主力净流入4018.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2581246817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581246817?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:15","pubTimestamp":1762330545,"startTime":"0","endTime":"0","summary":"11月05日, 药捷安康-B股价涨26.30%，报收228.60元，成交金额9.6亿元，换手率1.58%，振幅27.96%，量比2.72。药捷安康-B今日主力资金净流入4018.6万元，上一交易日主力净流出181.7万元。该股近5个交易日上涨24.58%，主力资金累计净流入4974.8万元；近20日主力资金累计净流入6407.5万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516200894f0788e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516200894f0788e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.1918},{"period":"3month","weight":0.0934},{"period":"6month","weight":11.4639},{"period":"ytd","weight":11.4639}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}